Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
about
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.Recommendations for imaging tumor response in neurofibromatosis clinical trials.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Auditory rehabilitation of patients with neurofibromatosis Type 2 by using cochlear implants.ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.Treatment of vestibular schwannoma cells with ErbB inhibitorsAR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.Temporal bone histopathology in neurofibromatosis type 2.The molecular biology of vestibular schwannomas and its association with hearing loss: a review.Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomasImatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.Merlin: the wizard requires protein stability to function as a tumor suppressor.Schwannomas and their pathogenesis.Therapeutics for childhood neurofibromatosis type 1 and type 2.Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.Chemoprevention for neurofibromatosis 2: just over the horizon?The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises.Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma.[Pathogenesis and molecular pathology of vestibular schwannoma].Pathogenesis and management of type 2 neurofibromatosisConsensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2
P2860
Q27853117-9343C115-7579-41C5-BDF6-3D7DC97D45AAQ30364937-BEBFE2DF-F471-453E-9946-BA4AF31A4EBCQ30389069-A6720F76-9A63-4582-86E0-297BC9B0B3A8Q30425757-FA3501B5-751D-4CAD-A339-264B898EAB6EQ30450038-E43AB84A-6753-4D54-8975-4D5F36493159Q30457595-E813F1A0-1A2E-4ADD-8129-1CCBC9B029DFQ30457869-C9212740-46C8-485A-A17D-8A9D4F55197BQ30458310-3B46376B-6CE1-4D5C-9956-2F9557CCC4BEQ30458767-7F2EC599-B15F-4622-BC16-266312BE3CDAQ30464276-C7FDF18B-AF96-479F-940B-70DBE58DA2C3Q30466218-C7CE8264-0164-4E5D-A351-1C8E2C80572CQ30467803-B2193B65-8EE4-44DC-8FDF-CBBCB0172371Q34062012-40F4B1D3-415A-40B8-A8A0-60CB7C673ED8Q37737382-27F63DE4-632D-443A-8054-DE65B3347010Q38023101-9C9C6431-2736-4D06-B98C-AA1E1637A00BQ38180808-BC4381EB-61F3-40FB-B07F-4F3B5DD924C9Q39716494-A81B23B5-8A22-485B-AB15-2B04D3CFEDD4Q40465319-72F0C129-FFDB-4234-91E2-D22A3C07C505Q41139111-23CDB895-97BF-482E-A878-E7DA287AF50DQ42408903-FA486C27-C8BB-4460-A94E-258424754F57Q47424261-A110AB7B-33B4-4C31-9065-C00DC4C1A288Q48743328-81FBB129-A705-45D6-9F42-03E7B65CED36Q50352494-47ED0181-A6D8-46B2-BCE0-90B75D176AA8Q52608968-F6FDAF2F-6D05-40A9-B614-ECFF8D0CB158Q52991168-A28D7C64-C89B-46E6-BCD2-AAA8D4BB6563Q57266478-92E880F7-68CD-4CEE-82CA-85104E8AF3C4Q57266579-AA0FD129-A854-46E8-B39C-E082DA539132
P2860
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
@ast
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
@en
type
label
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
@ast
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
@en
prefLabel
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
@ast
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
@en
P2093
P2860
P1476
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
@en
P2093
Chris Halpin
Fred G Barker
Jay S Loeffler
Michael J McKenna
Scott R Plotkin
Tracy T Batchelor
P2860
P304
P356
10.1097/MAO.0B013E3181EB328A
P577
2010-09-01T00:00:00Z